Contrast-induced nephropathy
| Contrast-induced nephropathy | |
|---|---|
| Synonyms | Contrast-induced acute kidney injury |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Nausea, vomiting, shortness of breath, edema |
| Complications | Acute kidney injury, chronic kidney disease |
| Onset | Within 48-72 hours after contrast exposure |
| Duration | Usually resolves within 1-2 weeks |
| Types | N/A |
| Causes | Iodinated contrast media |
| Risks | Chronic kidney disease, diabetes mellitus, dehydration, heart failure |
| Diagnosis | Serum creatinine increase, urinalysis |
| Differential diagnosis | N/A |
| Prevention | Hydration, use of low-osmolar or iso-osmolar contrast agents |
| Treatment | Supportive care, dialysis if severe |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | 1-2% in general population, up to 50% in high-risk patients |
| Deaths | N/A |
Contrast-induced nephropathy (CIN) is a form of kidney damage in which there has been recent exposure to medical imaging contrast material without another clear cause for the acute kidney injury. CIN is associated with a significant increase in morbidity and mortality, length of hospital stay and in healthcare costs.
Definition[edit]
Contrast-induced nephropathy is traditionally defined as a serum creatinine increase of 25% or more from baseline or an absolute increase of 0.5 mg/dL within 48-72 hours of intravascular iodinated contrast material exposure, in the absence of an alternative etiology.
Epidemiology[edit]
The incidence of CIN varies widely, depending on the definition used, the population studied, and the prophylactic measures taken. In the general population, the incidence of CIN has been reported to be less than 2%. However, in patients with pre-existing renal insufficiency, diabetes mellitus, or both, the incidence of CIN can exceed 25%.
Pathophysiology[edit]
The pathophysiology of CIN is complex and not completely understood. It is believed to involve direct toxicity to renal tubular epithelial cells and renal medullary hypoxia due to alterations in renal blood flow.
Prevention and Treatment[edit]
Prevention of CIN includes identification of high-risk patients, appropriate choice and dosing of contrast material, and prophylactic hydration. Treatment of established CIN is supportive, as there is currently no specific therapy available.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian